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The synthetic rexinoid bexarotene (Targretin, LGD1069)
inhibits the formation of both estrogen receptor-negative and
estrogen receptor-positive breast cancer in preclinical models
and controls the expression of growth-regulatory biomarkers,
such as IGFBP-6 (insulin-like growth factor-binding protein 6),
RAR, or cyclin D1. In this study, we identified a classical reti-
noic acid-responsive element in the first intron in the IGFBP-6
gene adjacent to a consensus AP-1 binding site, both elements
essential for rexinoid-induced expression of IGFBP-6. In chro-
matin binding experiments, bexarotene increased the occu-
pancy of the identified enhancer element by RXR, RAR, cJun,
cFos, and p300. In normal mammary epithelial cells and T47D
breast cancer cells, small interfering RNA-mediated knock-
down of all RXR isoforms or RAR, but not RAR or RAR
alone, blocked the induction of IGFBP-6 by bexarotene. Simul-
taneous knockdown of RAR and RAR abrogated both the
induction of RAR and the up-regulation and secretion of
IGFBP-6. The suppression of either RAR or cJun by small
interfering RNA blocked the recruitment of RXR and cJun to
the enhancer. These results demonstrate a novel cooperative
interaction between retinoid receptors and AP-1 orchestrated
by RAR and highlight a novel mechanism by which RAR can
mediate the cancer-preventive effects of rexinoids.
Retinoids are lipid-solublemediators that play essential roles
in development and homeostatic regulation. Retinoic acid and
its derivatives, such as 13-cis-retinoic acid, have been used for
the treatment of various cancers, including certain forms of
leukemia (1). In addition, retinoids and synthetic retinoid ana-
logues, such as 9-cis-retinoic acid, 13-cis-retinoic acid, orN-(4-
hydroxyphenyl) retinamide, have been shown to prevent cancer
in animals (2, 3) and in humans (4, 5).
We and others have shown that the panagonist 9-cis-retinoic
acid suppresses the development of breast cancer in mice and
rats (6, 7). However, this agent has significant toxicity. In con-
trast, RXR-selective retinoids or rexinoids, such as bexarotene
(LGD1069) and LG100268, were found to be very efficient in
suppressing the incidence of estrogen receptor-negative mam-
mary tumors in murine mammary tumor virus-ErbB2 mice (8,
9) without the typical toxicity of retinoids. In humans, bexaro-
tene was found to induce remissions in lymphoma patients and
thus has been approved by the Food and Drug Administration
for the treatment of cutaneous T-cell lymphomas (10). Bexaro-
tene is now being tested in a multicenter clinical trial for its
chemopreventive activity against breast cancer.
In a previous study of gene expression profiles of rexinoid-
induced biomarkers, we discovered that bexarotenemodulated
the expression of IGFBP-6 (insulin-like growth factor-binding
protein-6), along with other growth-regulatory genes, such as
COX-2, cyclin D1, and RAR (retinoic acid receptor ) (11, 12).
Insulin-like growth factors play a pertinent role in the growth
regulation ofmammary epithelial cells. Although IGF-I appears
to be a critical factor in the regulation of breast cell growth,
mice overexpressing IGF-II develop mammary tumors (13).
IGF-II is a mitogen for many different cancer cells, and overex-
pression of IGF-II gives rise to mammary tumors (14, 15). As
opposed to rodents, humans maintain high levels of IGF-II
throughout life, and its stromal expression suggests that IGF-II
may affect epithelial cell growth through paracrine pathways
in the breast (16). One of the important mechanisms to mod-
ulate the effect of IGFs in the tissues is to regulate the
amount of available IGFs2 through IGF-binding proteins (17),
with IGFBP-1 and -3 being the major IGF-I binding factors.
IGFBP-2 is frequently elevated in human prostate and brain
tumors and was suggested to play a role in PTEN signaling (18).
IGFBP-4, anearly responsiveestrogen-inducedgene, and IGFBP-5
as an estrogen-repressed gene, have been investigated as potential
predictive markers for endocrine therapy of breast cancer (19).
IGFBP-3 is themost abundant IGF-binding protein in circulation
carrying most of the circulating IGF, with intrinsic biologic ac-
tivities independent of its potential to sequester IGF (20, 21).
Although the biological effects of IGFBP-3 have been character-
izedbest, less is knownabout IGFBP-6. IGFBP-6has ahighaffinity
for binding IGF-II and is able to inhibit the growth of various can-
cer cells and activate programmed cell death pathways (22, 23). In
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addition, patients with invasive breast cancer had significantly
lower serum levels of IGFBP-6 than subjects with benign breast
disease (24). IGFBP-6 belongs to the small group of genes recently
identified as genes showing correlating expression profiles in
human estrogen receptor-positive breast tumors and the estrogen
receptor-positive cell lines T47D andMCF7 (25).
Here we have characterized the ability of the RXR-selective
retinoid bexarotene to regulate the expression of IGFBP-6. Our
results show that IGFBP-6 is up-regulated by the cooperative
action of retinoid receptors and the AP-1 transcription factor
through a complex response element in the first intron of the
IGFBP-6 gene. In addition, the early induction of RAR by
bexarotene is essential for the formation of an active AP-1/
RXR transcriptional complex, suggesting a novel mechanism
by which RAR can mediate the cancer preventive effects of
rexinoids.
MATERIALS ANDMETHODS
Ligands—The synthetic RXR-ligand bexarotene (Targretin,
LGD1069) was a kind gift of Dr. William Lamph (Ligand Phar-
maceuticals) and was used at a 1 M final concentration, unless
otherwise indicated. siRNA SmartPools and Dharmafect 1
transfection reagent were purchased from Dharmacon (Lafay-
ette, CO).
Cell Culture—Normal human mammary epithelial cells
(HMECs) were derived from healthy women who had under-
gone reduction mammoplasties and were purchased from
Clonetics (San Diego, CA). Cells
between passages 4 and 12 were
used. HMECs were maintained in
mammary epithelial basal medium
supplemented with 50 g/ml bovine
pituitary extract, 5 g/ml insulin, 10
ng/ml human recombinant epider-
mal growth factor, 0.5 g/ml hydro-
cortisone, 30 g/ml gentamicin, and
15ng/ml amphotericin-B (Clonetics).
Cells were cultured in a humidified
environment at 37 °C with 5% CO2
in the air. The human breast can-
cer cell lines T47D and MCF-7
were obtained from the ATTC
(Manassas, VA) and maintained in
Iscove’s modified Eagle’s medium
containing 10% fetal bovine serum
(Invitrogen).
RNA Extraction andMeasurement
of Transcript Levels—Total RNAwas
extracted using the RNeasy kit
from Qiagen according to the
manufacturer’s instructions. Reverse
transcriptionwas performed in tripli-
cate, with a “non-reverse transcrip-
tion control” lacking reverse tran-
scriptase in parallel, to control
amplifications due to genomic DNA
contamination. Transcript quantita-
tion based on real timemonitoring of
amplificationwascarriedoutusingan
ABI7700 sequenceanalyzerperform-
ing 40 cycles of 95 °C for 12 s and
60 °C for 30 s. Values of transcripts in
unknown samples were obtained by
interpolating their Ct (PCR cycles to
threshold) values on a standard curve
derived from known amounts of cog-
FIGURE 1. Characterization of the effect of the RXR-selective agonist bexarotene (LGD1069, Targretin)
on the expression of IGFBP-6. A, comparison of the effects of bexarotene on the transcript levels of IGFBP-6
measured in normal and transformedmammary epithelial cells. Cells were treated with either DMSO/ethanol
(50:50%, v/v) as vehicle (Veh) or 1 M bexarotene (Bex) for 24 h. Relative molecule numbers of IGFBP-6 mRNA
were measured by quantitative reverse transcription-PCR normalized to those of cyclophilin, and values in
rexinoid-treated cells are expressed as -fold change over vehicle treatment. Statistical significance of the
changes was determined by Student’s t test. *, p  0.05. Inset, IGFBP-6 protein levels after 48 h of vehicle or
bexarotene treatment in the corresponding cell lines, as determined by Western blot. The numbers represent
normalized expression levels relative to controls. B, dose-response curve. HMECs were treatedwith increasing
dosesofbexarotene (10nM to10M), andRNAwasharvested24h later. IGFBP-6RNAexpressionwasmeasured
usingquantitative reverse transcription-PCRandexpressedas apercentageof cyclophilin.C, timedependence
of the induction of IGFBP-6mRNA by 1M bexarotene in HME cells.D, comparison of the effect of bexarotene
over vehicle on the expression of IGFBP-6 in cells with or without pretreatment with cycloheximide (CHX).
TABLE 1
Relative mRNA levels of IGF-binding proteins in normal mammary
epithelial cells are shown S.D.
Relative mRNA levels were expressed per 106 of cyclophilin molecules.
Vehicle Bexarotene
IGFBP-1a 4 1 3 0
IGFBP-2 74,244 21,260 95,845 28,967
IGFBP-3a 619 85 1671 191
IGFBP-4 1293 241 1134 146
IGFBP-5 9 4 8 2
IGFBP-6a 683 73 1660 460
a Significant difference between vehicle and LGD1069 at p 0.05.
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nate, amplicon-specific synthetic oligonucleotides.Transcript lev-
els were normalized to the level of cyclophilin mRNA.
Selective Gene Knockdown Experiments—To assess the effect
of gene silencing on the consequent changes in transcript levels,
104 cells were seeded on 24-well tissue culture plates 24 h prior
to transfection. Transfection conditions were optimized for
highest level of knockdown at the lowest toxicity, and the active
individual duplexes were identified for combination knock-
down experiments. Suppression of transcript levels exceeding
70% was considered acceptable.
Generation of Reporter Constructs—Noncoding regions of
the IGFBP-6 gene (accessionnumberAJ006952)were amplified
by polymerase chain reaction using the genomic clone RP11-
158-I20 as a template. Fresh PCR products were TA-cloned
into aTOPO2.1TA-cloning vector (Invitrogen) and then trans-
ferred to the pGL3 basic luciferase reporter vector (Promega,
Madison, WI). Site-directed mutagenesis was carried out
using the QuikChange mutagenesis (Stratagene) protocol
according to the manufacturer’s recommendations. Three
point mutations were introduced in the distal AP-1 binding
site (AP1mut31; TGAGTCA 3 TTATTAA) and two into
the RXRE (RXRmut23; AGGTCA3 AGTTAA).
Reporter Assays—Reporter assays of luciferase expression
vectors were carried out to assess the retinoid responsiveness of
various regulatory regions of the IGFBP-6 gene promoter and
introns. Transfections were conducted overnight in cells plated
in 24-well tissue culture plates at70% confluence, using 0.6l
of FuGene6 transfection reagent (Roche Applied Science) and
0.2 g of plasmid DNA in each well. Treatments were done in
triplicate, and experiments were repeated three times. Meas-
urements were performed using the Dual-Reporter Assay Kit
(Promega, Madison, WI) on a Luminoskan apparatus. To con-
trol for variations in transfection efficiency, firefly luciferase
readings were normalized to the activity of the anthozoan
Renilla reniformis luciferase enzyme expressed from a consti-
tutive promoter.
Western Blot—Cells were transfected with siRNAs for nu-
clear receptors or luciferase, as a control. Forty-eight hours
later transfected cells were treated with bexarotene or vehicle.
Another 24 h later, cell supernatants were harvested, and pro-
teins fromwhole cell lysates were extracted usingmethods pre-
viously described (11). Equal amounts of total protein were
electrophoresed on a 10% acrylamide denaturing gel and trans-
ferred onto a polyvinylidene difluoride membrane. Protein lev-
els were detected by using the following antibodies: rabbit poly-
clonal antibody specific for IGFBP-6 at 1:200 (catalog number
PB-383-9; Austral Biologicals, San Ramon, CA), RXR (D-20,
sc-553), RAR (C-20, sc-551), RAR (C-19, sc-552X), RAR
(C-19, sc-550; Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
and mouse monoclonal antibody specific for -actin (catalog
number sc-7202; Santa Cruz Biotechnology; 1:200). The blots
were visualized using the enhanced chemiluminescence West-
ern blot detection system (Amersham Life Sciences).
Chromatin Immunoprecipitation (ChIP) Assay—Chromatin
immunoprecipitation assays were performed as described
before (26). Briefly, cells were grown for 4 days in 15-cm dishes
to 60% confluence and kept in serum-free media for another
48 h before drugs were added. After washing in PBS, cells were
fixed in 1% formalin for 15 min. Cellular DNA was fragmented
by sonication with 8 times 5 pulses at power output 5 (Branson
Sonifier 450). 500g of cell lysateswere preclearedwith protein
G-agarose, and the transcription factors in the supernatant
FIGURE 2. Characterization of the effects of individual and combined
knockdown of retinoid X receptors and retinoic acid receptors on the
response of IGFBP-6 to bexarotene. A, RXR expression following siRNA-
mediated knockdown inHMECs.mRNA levelsweremeasuredbyquantitative
reverse transcription-PCR. Inset, RXR protein levels in cells transfected with
nonspecific (NS) or RXR-specific (RXR) siRNA. The numbers indicate protein
abundance normalized to glyceraldehyde-3-phosphate dehydrogenase, rel-
ative to control. B, IGFBP-6mRNA levels following transfection of HMECswith
RXR siRNAs. C, comparison of the effects of nonspecific and RXR-specific
siRNAs on the induction of IGFBP-6 by bexarotene. Top, RXR mRNA levels in
cells transfected with control (siNS) or the combination of RXR, -, and -
siRNAs. Bottom, mRNA levels of IGFBP-6 following knockdownof RXR, RXR,
andRXR.D, top, expression levels of RARs following siRNAknockdownof the
individual receptors in HMECs. Bottom, induction of IGFBP-6 mRNA by bex-
arotene in HMECs following knockdown with a nonspecific siRNA (siNS) or
siRNAs against RAR, RAR, or RAR.
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were immunoprecipitated using antibodies against RXR, RXR,
RAR, RAR, RAR, cJun, cFos, ATF2, and p300. Normal rabbit
IgGwas used as negative control. After reversal of the cross-links,
DNA was extracted, and the 2530–2700 section of intron 1 of
IGFBP-6 was amplified by 32 cycles of PCR. To ensure reproduc-
ibility, experiments were repeated three times. DNA products
were first analyzed on 1.5% agarose gels. For accuracy and
increasedsensitivity todetect chromatinprecipitatedby theRAR
antibody, extracted DNA was also measured by quantitative real
time PCR. Optimal efficiency and linear nature of the reactions
was determined by constructing a standard curve from serial dilu-
tions of the BAC clone containing the IGFBP-6 gene.
Statistical Analysis—Statistical significance was determined
using Student’s t test or two-tailed analysis of variance. A p
value of 0.05 was considered statistically significant. Values
are presented as means S.D.
RESULTS
IGFBP-6 Is Induced by Bexarotene and Is Growth-suppressive—
We previously identified IGFBP-6 as a marker gene of the che-
mopreventive rexinoid bexarotene (Targretin, LGD1069) in
normal HMECs. In previous microarray experiments, IGFBP-6
was found to be up-regulated (mean change 2.8-fold at p 
0.05) by treatment with 1 M bexarotene (among 12,384 genes
present on the oligonucleotide chip)
(11). This result stimulated us to
investigate the molecular mecha-
nism by which rexinoids induce
IGFBP-6 expression. To understand
what components of the IGF system
may be affected by this rexinoid, we
first measured the effect of bexaro-
tene on themRNA levels of the IGF-
binding proteins 1–6 in HMECs
after a 24-h exposure to the drug
using real time quantitative reverse
transcription-PCR. These studies
showed that IGFBP-2 mRNA was
most abundant in HMECs, whereas
IGFBP-1 and -5 were barely detect-
able (Table 1). As shown in Table 1,
bexarotene increased the expres-
sion of IGFBP-3 and IGFBP-6.
Nuclear Hormone Receptors
Involved in Rexinoid-dependent
Induction of IGFBP-6—We next
confirmed that bexarotene induced
IGFBP-6 in normal mammary epi-
thelial cells and in multiple breast
cancer cell lines. These studies
showed an average 3–4-fold in-
crease in the mRNA levels of
IGFBP-6 upon the addition of 1 M
bexarotene to normal breast cells
and breast cancer cells (T47D and
MCF-7) (Fig. 1A). Increased levels
of the mRNA were followed by the
induction of the IGFBP-6 protein as
well (Fig. 1A, upper inset). Based on the log-linear section of the
dose-response curve, 1 M concentration of bexarotene was
chosen for treatment in further studies (Fig. 1B). As shown in
Fig. 1C, the up-regulation of the IGFBP-6 mRNA occurred in a
delayed fashion, reaching close to maximal change at 24 h,
suggesting that the induction involves an indirect mechanism.
The requirement of a retinoid-inducible intermediary factor for
the up-regulation of IGFBP-6 was demonstrated by the lack of
induction in the presence of cycloheximide prior to addition of
bexarotene to the culture media (Fig. 1D).
In order to confirm that the effect of bexarotene is RXR-de-
pendent, we treated HMEC and T47D cells with the rexinoid
after suppressing RXRs by specific siRNAs. Suppression of
RXR was seen as assessed at the level of mRNA (see Fig. 3A)
and protein (Fig. 2A, inset) and by immunohistochemistry (data
not shown). However, loss of RXR resulted in no significant
change in the induction of IGFBP-6 by bexarotene (Fig. 2B).
Similarly, individual knockdown of RXR or RXR isoforms
alone had no significant effect (data not shown). However,
simultaneous knockdown of all three RXR isoforms diminished
the induction of IGFBP-6 (Fig. 2C). Thus, RXR proteins are
required for rexinoid induction of IGFBP-6; however, the dif-
ferent RXR isoforms are redundant in their ability to stimulate
IGFBP-6 expression in response to rexinoid.
FIGURE 3. The role of RAR in the induction of IGFBP-6. A, time course of the mRNA levels of RAR in HMECs
treatedwith vehicleor 1Mbexarotene.B, combinedknockdownofRARandRAR inHMECs. Top, suppressionof
RARandRARmRNAsupon transfectionwithgene-specific siRNAs.Bottom, changes in theprotein levels of RAR
andRAR following48-hknockdownbycombinedsiRNAs.C, theeffectofcombinedknockdownofRARandRAR
on RAR and IGFBP-6 expression. Top, RARmRNA levels upon Bex in HMECs transfectedwith nonspecific control
siRNAor siRNAs against RAR andRAR.Middle, IGFBP-6mRNA levels after Bex inHMECs transfectedwithnonspe-
cific control siRNA or siRNAs against RAR and RAR. Bottom, Western blots showing the levels of cellular RAR in
response toBex inHMECs transfectedwithnonspecific control siRNAor siRNAsagainst RARandRAR.D,Western
blotsdemonstrating changes in the levels of secreted IGFBP-6 in response tobexaroteneor vehicle in tissue culture
media of HMECs following knockdownwith a nonspecific siRNA (siNS) or siRNAs against RAR and RAR.
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To determine which potential RXR partner receptors may
mediate the induction of IGFBP-6, we knocked down RAR,
RAR, or RAR prior to the addition of bexarotene. All of these
receptors had detectable transcript levels at base line, with
RARmRNA levels being less than 2% of that of RAR and less
than 0.75% of RAR. siRNA treatment of retinoic acid recep-
tors resulted in at least 70% suppression of their mRNAs, as
determined by quantitative reverse transcription-PCR (Fig. 2D,
top). Knockdown of RAR was able to block the up-regula-
tion of IGFBP-6 (Fig. 2D, bottom),
whereas suppression of RAR or
RAR did not abrogate but only
partially reduced the response of
IGFBP-6 to bexarotene. Similar re-
sults were obtained when repeating
the knockdown experiments in
T47D cells (data not shown).
Induction of RAR Is Critical for
the Rexinoid-dependent Up-regula-
tion of IGFBP-6 Expression—As
shown in Fig. 2D, RAR was the
only retinoid receptor whose knock-
down alone blocked the rexinoid
response of IGFBP-6. Although
RAR is expressed at a low level in
untreated cultured cells, the time
course of RAR expression shows
that RAR is greatly induced as early
as 3h followingbexarotene treatment
(Fig. 3A), and cells sustained elevated
protein levels of RAR 48h after rexi-
noid exposure (Fig. 3C, bottom).
Simultaneous suppression of
RAR and RAR by siRNAs in
HMECs reduced their mRNA levels
by over 80% and protein levels cor-
respondingly (Fig. 3B). The com-
bined knockdown of RAR and
RAR greatly inhibited the induc-
tion of RAR by bexarotene (Fig.
3C, top). Furthermore, the lack of
induction of RAR in RAR/ -sup-
pressed cells was associatedwith the
abrogation of the up-regulation of
IGFBP-6 transcript levels and pro-
tein by bexarotene (Fig. 3, C (mid-
dle) and D), suggesting that the
induction of RAR is critical for the
up-regulation of IGFBP-6.
Identification of the Bexarotene-
responsive Elements in the IGFBP-6
Gene—To further elucidate the me-
chanismbywhich retinoids regulate
the expression of IGFBP-6, we iso-
lated the 5-regulatory sequences,
including the 5-untranslated re-
gion, of the IGFBP-6 gene upstream
of the coding region and cloned a
series of deletion constructs into the luciferase reporter vector
pGL3 basic (Fig. 4A). The expression vectors containing these
promoter fragments were transiently transfected into HMECs
and T47D cells, and the bexarotene-dependent increase of
luciferase activity was assayed. None of the reporter constructs
spanning the proximal 2 kb of the putative IGFBP-6 promoter
exhibited increased activity upon the addition of bexarotene
(Fig. 4B). Therefore, the three introns and the 3-untranslated
region of the IGFBP-6 gene were also cloned and tested. All of
FIGURE 4. Identification of rexinoid-responsive elements within the IGFBP-6 gene. A, promoter segments
of the IGFBP-6 gene (2104 to 80) inserted in the pGL3 basic luciferase vector. B, luciferase activity of the
IGFBP-6 promoter constructs in bexarotene-treated HMECs expressed as -fold change over vehicle treatment.
Reporter activitywasmeasuredusing thedual luciferase assay (Promega), andenzymeactivitywas normalized
to Renilla luciferase activity. C, schematic diagram of the reporter constructs containing serial deletions of the
distal region of intron 1 from the IGFBP-6 gene. D, comparison of the luciferase activity in HMECs transfected
with IGFBP-6 intronic reporter constructs and treated with vehicle or 1 M bexarotene.
Retinoid Receptors and AP-1 Co-Regulate IGFBP-6
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the resulting reporter constructs proved unresponsive to bex-
arotene, with the exception of one containing the distal region
of intron 1. Within this segment, spanning 650 bp (Fig. 4C,
positions 2531–3180 in the IGFBP-6 gene), we identified an
intronic region that showed identical response to bexarotene
as the native IGFBP-6 gene. By creating a series of deletion
mutants, we found that this rexinoid-responsive region is a
complex regulatory element comprising 112 bp (2512–2623;
Fig. 4D).
To identify relevant intron 1 response elements, this intron 1
region was studied in silico using the Transcription Element
Search Software (available on theWorldWideWeb). The anal-
ysis suggested that the rexinoid-responsive region of intron 1
contains potential response elements for AP-1, RXR-RAR, Sp1,
TTF1, and AP-3 between the locations 2512 and 2623 (Fig. 5A).
Therefore, we next created and tested various 5, 3, and inter-
nal deletion constructs of intron 1 to determine which of these
elements were functionally required for the activity of the con-
struct (Fig. 5B). Induction of the luciferase reporter gene upon
bexarotene treatment was moderate but was highly reproduci-
ble overmultiple experiments (significant at p 0.005 between
groups by two-way analysis of variance). Removal of the proxi-
mal, overlapping AP-1/RXR-RAR response elements (see con-
struct 2) did not reduce the activity of the reporter (compare
construct 2 with construct 1; Fig. 5B). However, deletion of the
DR5 consensus RXR-RAR response element (AGGTCA-5-
GGGACA) at position 2605–2622 (construct 3) completely
eliminated the bexarotene response of the reporter (Fig. 5B).
When the AP-1 binding site (TGAGTCA) upstream of the RXRE
was deleted (Del 2557–2603) while the distal RXRretinoic acid
responseelementwas left intact, againall response toretinoidswas
lost. To establish whether the distal RXR and AP-1 binding sites
are indeed critical, these putative response elements were individ-
ually altered by site-directed mutagenesis. Inactivation of either
the putative distal RXRE (construct 5, RXRmut23, 2605–2610) or
the AP-1 response element (construct 6, APmut31, 2593–2599)
resulted in significant reduction or the abrogation of the bexaro-
tene response. Similar results were obtained in both T47D and
HMECs, demonstrating that both the distal RXRE and the adja-
cent AP-1 elements are required in rexinoid-induced transactiva-
tion of the IGFBP-6 gene.
To determine which transcription factors in vivo bind the
regulatory region shown to be bexarotene-responsive in re-
porter assays, we performedChIP assays inT47Dcells targeting
the rexinoid-responsive region of intron 1 (Fig. 6A). In the
absence of bexarotene, this segment was occupied by cJun and
ATF2 and showed weak binding of RXR, RXR, and the coac-
tivator p300 (Fig. 6B), suggesting that in the inactive state, a
cJunATF2 heterodimer binds the element. Serial ChIP assays
indicated that upon the addition of bexarotene, increased bind-
ing of RXR to the active intronic segment occurred no earlier
than 12 h (data not shown). Further ChIP analyses showed that
recruitment of RXR and cJun were the dominant changes on
the response element, but increased binding of cFos, RAR, and
p300 were also observed (Fig. 6, B and C). At the same time,
bexarotene treatment markedly reduced its occupancy by
ATF2 and RXR (Fig. 6, B and C). Enhanced recruitment of
RAR upon bexarotene could be detected by quantitative real
time PCR but not conventional PCR analyzed on gel (Fig.
6C). The concurrent binding of AP-1 and retinoid receptors
is consistent with our reporter assay data showing that selec-
tive deletion of either the RXR-RAR response element or the
FIGURE 5. Analysis of reporter constructs to identify responsive elements to bexarotene in intron 1 of the IGFBP-6 gene. A, sequence and putative
response elements (underlined) of the bexarotene-responsive fragment (positions 2512–2623) of intron 1 of the IGFBP-6 gene. Nucleotides replaced by
site-directedmutagenesis of the putative AP-1 and RXR-response elements are highlighted. B, comparison of internal deletion reporter constructs (left) of the
2512–2623 fragment of intron 1 of IGFBP-6 created to identify critical response elements to bexarotene. Luciferase activity was measured (right) in HMECs
treated with vehicle or 1 M bexarotene after transfection with reporter constructs harboring deletions of individual response elements within the
2512–2623 fragment of intron 1 of the IGFBP-6 gene. Data represent the means of normalized light units  S.D. from five different experiments
(performed in triplicate) graphed as -fold induction over vehicle-treated controls. Statistical significance of the changes was determined by two-way
analysis of variance tests. *, p  0.005.
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AP- 1 site abrogates the activation of the bexarotene-respon-
sive construct.
Both RAR and cJun Are Required for the Recruitment of
RXR to the IGFBP-6 Gene—To determine whether RAR is
essential for the recruitment of transcription factors to the rexi-
noid-responsive IGFBP-6 enhancer, we performed chromatin
immunoprecipitation experiments in bexarotene-treated cells
following the knockdown of RAR. The suppression of RAR
was associatedwith the loss of recruitment of RXR and cJun to
the enhancer in response to bexa-
rotene (Fig. 6D). Conversely, ATF2
binding markedly increased upon
bexarotene treatment, whereas
binding of cFos diminished (data
not shown). In a parallel experi-
ment, the siRNA-mediated sup-
pression of cJun removed cJun and
decreased RXR occupancy to the
response element. This demon-
strates that the cooperative action
of AP-1 and induced RAR are nec-
essary for the recruitment of RXR
to the IGFBP-6 gene.
Based on these observations, we
propose the model shown in Fig. 7
to explain how bexarotene induces
the expression of IGFBP-6. In un-
stimulated cells or in the absence
of elevated levels of RAR, the
identified response element in in-
tron 1 of the IGFBP-6 gene may be
occupied by ATF2cJun and RXR
RAR or -dimers and remains inac-
tive (Fig. 7, left). Treatment of the
cells by the cancer-preventive rexi-
noid bexarotene results in the early
induction of RAR, which binds
RXR proteins, in particular RXR
(Fig. 7, right). This dimeric RXR
RAR complex then binds to the
IGFBP-6 intron, displaces RXR
and ATF2, and causes recruitment
of cJun and cFos, which then facil-
itates binding of p300 and RNA
polymerase II, ultimately inducing
IGFBP-6 mRNA expression, through
a unique collaboration between com-
plexes of RXRRARheterodimers and
JunFos heterodimers.
DISCUSSION
In the present study, we charac-
terized the ability of the RXR-selec-
tive retinoid bexarotene to up-regu-
late the expression of IGFBP-6. We
demonstrated that bexarotene reg-
ulates IGFBP-6 through a complex
enhancer element in intron 1 of the
gene, and this regulation requires permissive interaction between
the AP-1 transcription factor complex and RXRRAR het-
erodimers. Although the involvement of RAR is essential for the
bexarotene-induced up-regulation of IGFBP-6, its own induction
requires RAR or RAR. As shown in Fig. 7, induction of RAR
leads to the recruitment of RXR, the displacement of ATF2 and
RXR, and the binding of a cJuncFos heterodimer, ultimately
recruiting the cofactor p300 and RNA polymerase II to drive the
induction of IGFBP-6.
FIGURE 6. ChIP assay in T47D cells to assess recruitment of transcription factors to the rexinoid-respon-
sive fragment of the IGFBP-6 gene after 12 h of bexarotene treatment. A, design of the PCR assay encom-
passing the bexarotene-responsive element in intron 1 of IGFBP-6. B, PCR amplification of the DNA segment
2524–2697 following chromatin immunoprecipitationwith antibodies against RXR, RXR, RAR, RAR, cJun,
cFos,ATF2, andp300.Normal rabbit IgGwasusedasnegative control.C, determinationof immunoprecipitated
chromatin upon bexarotene treatment using quantitative real time PCR. Samples were normalized to their
respective input, and values are expressed relative to vehicle-treated counterparts. D, binding of RXR in the
presence or absence of RAR or cJun to the IGFBP-6 gene. Chromatin IP detecting recruitment of RXR and
cJun to the bexarotene-responsive site of IGFBP-6 in controls (si NS) and cells after depletion of RAR or cJun
(siRAR, si cJun).
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In previous studies of rexinoid-induced biomarkers, we dis-
covered that bexarotenemodulated the expression of IGFBP-6,
along with other growth-regulatory genes, such as COX-2,
cyclin D1, and RAR (11). Because the effect of IGFs in the
tissues is modulated by the abundance of IGF-binding proteins
(17), the regulation of IGF-binding proteins by bexarotenemay
contribute to the cancer-preventive activity of the rexinoid.
IGFBP-6 has a high affinity for binding IGF-II and is able to
inhibit the growth of various cancer cells and activate pro-
grammed cell death pathways (22, 23). The pleiotropic effects
of RXR-selective retinoids make it likely that the cancer-pre-
ventive effect of this class of agents is due to regulation of many
genes. However, understanding how bexarotene regulates
IGFBP-6 helps create the next set of biomarkers that can be
used as surrogates of breast cancer as an end point of clinical
studies. Furthermore, themechanism and exact composition of
the transcriptional complexes occupying promoters or enhanc-
ers in biomarker genes reveal novel targets for new, improved
chemopreventive agents with better efficacy and less toxicity.
IGFBP-6 has a high affinity for binding IGF-II and is able to
inhibit the growth of various cancer cells (22, 23) and low serum
levels of IGFBP-6 in patients correlated with invasive breast
cancer (24). Recombinant IGFBP-6 in physiologic concentra-
tions is able to suppress growth of HMECs.3 However, blocking
IGFBP-6 expression using siRNAs did not reverse the antipro-
liferative effect of bexarotene in breast epithelial cells, indicat-
ing that the induction of IGFBP-6 is not solely responsible for
the growth-suppressive effects and possibly the cancer-preven-
tive activity of this rexinoid. Indeed, we have previously shown
that rexinoidsmodulatemany growth-regulatory genes, such as
cyclin D1, RAR, or COX-2, in addition to IGFBP-6. These
results strongly suggest that rexinoids act through a network of
pathways to suppress cancer formation.
RAR has been shown to distinctly mediate the growth-in-
hibitory effect of retinoids and as such is a potential target for
cancer-preventive treatment (27–
29). Silencing of the RAR gene and
repressing methylation of the pro-
moter were shown to be causative
reasons in the genesis of various
cancers (30, 31). Studies in RAR
(/) teratocarcinoma cells have
identified genes that were specifi-
cally regulated by RAR(2) (32).
Similarly, our data show that RAR
plays a critical role in the induction
of IGFBP-6 and cannot be substi-
tuted by other RARs. However, in
breast epithelial cells, the abun-
dance of RAR is low, and the up-
regulation of IGFBP-6 is preceded
by the induction of RAR. The
RAR gene is directly regulated by
RXRRAR heterodimers through a
classical retinoic acid response ele-
ment, and its expression can occur in a tissue-specific manner.
The knockdown and chromatin binding experiments further-
more indicate that although RAR or RAR is required for the
up-regulation of RAR, they are not sufficient to activate the
intronic bexarotene-responsive enhancer of IGFBP-6.
A high level of redundancy was observed on the IGFBP-6
gene with retinoid X receptors. Although ChIP results indicate
that RXR binding to the response element is not needed for
gene induction, individual knock-down of RXR was not suffi-
cient to abrogate it. This suggests that RXR can substitute for
RXR when the latter is depleted. Because RXR is not detect-
able in these cells (data not shown), this isoform is unlikely to
participate in the regulation of IGFBP-6.
Our results demonstrate that the AP-1 transcription factor
also has an integral role in the regulation of IGFBP-6 expres-
sion. Our data showed a reciprocal relationship between cFos
andATF2, where cFos and cJun replacedATF2 on the response
element during activation of IGFBP-6. ATF2 (activating tran-
scription factor 2, CREBP, HB16, CREB2) is a member of the
ATF/CREB family of transcription factors. ATF2 binds the pro-
moters of various viral and cellular genes, many of which are
important in cell growth and differentiation. Loss of ATF2 can
promote formation of breast cancer (33). TheATF2protein can
form either homodimers or heterodimers with cJun and other
members of the ATF/CREB and Jun/Fos families. Thus,
increased binding of ATF2 to the enhancer may compete off
cFos fromactive cFos-cJun heterodimers.Our data suggest that
an ATF2-cJun dimer is either inhibitory or at best an inactive
complex on the IGFBP-6 enhancer element. Replacement of
the ATF2-cJun dimers by cJuncFos heterodimers greatly
increased transactivation of the enhancer and suggests that
cJuncFos heterodimers can enter a permissive interaction with
RXRRAR heterodimers. ATF2 and p300 can cooperate in the
control of transcription by forming a protein complex that is
responsive to differentiation-inducing signals, such as retinoic
acid or E1A (34). However, on the IGFBP-6 enhancer element,
greater p300 occupancy was seen upon formation of an AP-1/
retinoid receptor complex and decreased ATF2 binding.
3 I. P. Uray, Q. Shen, H.-S. Seo, H. Kim,W.W. Lamph, R. P. Bissonnette, and P. H.
Brown, unpublished observation.
FIGURE 7. The role of RAR induction and RXR-AP1 cooperation in the regulation of IGFBP-6. Shown is a
schematic diagram showing the state of the rexinoid-responsive gene IGFBP-6 in the absence (A) or presence
(B) of bexarotene.
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In neuroblastoma cells, the AP-1 activator TPA up-regulates
IGFBP-6 (35). In our experiments, suppression of cFos levels by
siRNA causes decreased base-line expression and blunts the
induction of IGFBP-6 inHMECs (data not shown). Previous stud-
ies showed that growth suppression by retinoids is associatedwith
AP-1 antagonism (36), and retinoid-induced inhibition of AP-1
was dependent on the orphan receptor COUP-TF (37). In partic-
ular, RAR-selective ligands were shown to inhibit AP-1 and
induce apoptosis in breast cells (38).Gel shift assays demonstrated
that RXR inhibits Jun and Fos DNA binding and that 9-cis-reti-
noic acid enhances this inhibition, suggesting that a mechanism
involving direct protein-protein interaction between RXR and
AP-1 components mediates the inhibitory effect observed in vivo
(39). Furthermore, domains of RAR responsible for the inhibitory
action of retinoids on AP-1 activity were identified (40). These
studies and the natural functional antagonism demonstrated by
retinoids and mitogenic pathways ending on AP-1 suggest that
genes with antioncogenic properties would be regulated in an
opposing manner by retinoid receptors and AP-1. This discovery
indicates that, depending on the cellular context and the mecha-
nism of action of the drug used, AP-1 may be involved in regula-
tory mechanisms that counteract cell proliferation. This notion
opens a new path to the development of pharmacological agents
that aim tomodulate AP-1 activity.
The studies presented here demonstrate a novel mechanism
of cooperative action of the AP-1 transcription factor and reti-
noid receptors through a complex response element in the first
intron of the IGFBP-6 gene. Furthermore, we demonstrate that
bexarotene-induced RAR is essential for the formation of an
active AP-1/RXR transcriptional complex, revealing a novel
mechanism by which RAR canmediate the tumor-preventing
effects of RXR-selective retinoids.
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